CardiAMP is a cell therapy commercialized by BioCardia, with a leading Phase III program in Systolic Heart Failure. According to Globaldata, it is involved in 5 clinical trials, of which 3 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of CardiAMP’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for CardiAMP is expected to reach an annual total of $21 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
CardiAMP Overview
BioCardia Overview
BioCardia is a regenerative medicine company. The company’s pipeline products include autologous BCDA-01 and NK1R+ Allogeneic BCDA-03 is for the treatment of ischemic heart failure. Autologous BCDA-02 for chronic myocardial ischemic. NK1R+ allogeneic BCDA-04 treats covid-19 acute respiratory distress syndrome (ARDS). It also offers cell processing and cell delivery enabling products including cardiamp cell processing platform, helix transendocardial biotherapeutic delivery system, morph universal deflectable guide catheter, morph accesspro sheaths, among others. The company sells its products through a network of distributors across the US. BioCardia is headquartered in San Carlos, California, the US.
The company reported revenues of (US Dollars) US$0.5 million for the fiscal year ended December 2023 (FY2023), a decrease of 64.7% over FY2022. The operating loss of the company was US$11.6 million in FY2023, compared to an operating loss of US$11.9 million in FY2022. The net loss of the company was US$11.6 million in FY2023, compared to a net loss of US$11.9 million in FY2022.
For a complete picture of CardiAMP’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
